Microsoft word - iv push policy updated final may 201
The University of Kansas Hospital Corporate Policy Manual Volume: Patient Care Section: Medication Management POLICY Title: Administration of IV Push Medications on non-critical care units
Signature __________________________________________________________________
Tammy Peterman / Executive Vice-President, Chief Operating Officer,
Formulation:___4/2009______ Revised:_____05/2011______ Reviewed:__________________ Date
Contact Person Responsible for Policy Updates: Joann Lacy, Pharmacy Clinical Coordinator WORKFORCE GROUP TO BE TRAINED ON THIS POLICY
Purpose:
To establish guidelines for the administration of IV push medications on non-critical care units.
Only registered nurses that have successfully validated basic IV competency can administer IV push medications on non-critical care units.
Only designated intravenous medications that have been approved by the Pharmacy and Therapeutics Committee may be administered by IV push on non-critical care units.
These guidelines are to be used with adult patients (≥17 yrs.) only.
The administration rates are guidelines and may be changed by the physician to meet the individual needs of the patient.
The nurse should consult with the physician or clinical pharmacist if there is a question about the safe administration of the drug.
An IV medication reference must be readily available on each nursing unit.
Emergent treatment situations are not restricted by the guidelines of this policy.
This policy does not include clotting or coagulation factors that may be pushed according to manufacturer recommendations.
This policy does not include chemotherapy medications that may be pushed according to manufacturer recommendations by a chemotherapy competency validated registered nurse.
RATE OF ADMINISTRATION DRUG APPROVEDIV PUSHRANGE DILUTION COMMENTS/MONITORING Atropine Aztreonam (Azactam®) Bumetanide (Bumex® ) Butorphanol (Stadol®) Cefazolin (Ancef®) Cefotaxime (Claforan®) Cefoxitin (Mefoxin®)
Each 1 gram diluted with at least 10 mL of normal saline. Vials and
Ceftazidime (Fortaz®)
syringes must be vented after dilution and before administration.
Ceftriaxone (Rocephin®) Cefuroxime (Zinacef®) Dexamethasone (Decadron®) Dextrose 50% (50gm/100mL) Undiluted. Not compatible with Diazepam (Valium®) Diphenhydramine (Benadryl®)
Administer slower in non-emergent situations.
Droperidol (Inapsine®) – SEE symptoms. Doses > 2.5mg should be administered via PB.
Each dose over 1 minute. Intravenous route is preferred for patient with chronic renal failure Epoetin Alpha (Epogen®) on hemodialysis. Subcutaneous administration is preferred in other populations. Esomeprazole (Nexium®) Estrogens, conjugated (Premarin®)
mL sterile diluent in package. Do not shake.
Famotidine (Pepcid®) Fentanyl Furosemide (Lasix®) Glycopyrrolate (Robinul®) Granisetron (Kytril) Haloperidol lactate (Haldol®) RATE OF ADMINISTRATION DRUG APPROVEDIV PUSHRANGE DILUTION COMMENTS/MONITORING Hydrocortisone sodium succinate (Solu-Cortef®) Hydromorphone (Dilaudid®)
Through saline-lock IV: Dilute to total of 5mL with NS, D5W, or SW
Insulin, Human Regular Ketorolac (Toradol®)
Dilute 500 mcg vial with 5 mL of preservative-free normal saline. Use
Levothyroxine sodium (Synthroid®) Lorazepam (Ativan®) Meperidine (Demerol®)
Through saline-lock IV: Dilute to total of 5mL with NS, D5W, or SW
Meropenem (Merrem®) Mesna (Mesnex®) Methylprednisolone (Solu-Medrol®) Methylthionine Chloride (Methylene
Each 10mg or fraction thereof over 2 minutes.
Metoclopramide (Reglan®) Doses greater than 10 mg should be administered via PBMorphine
Through saline-lock IV: Dilute to total of 5mL with NS, D5W, or SW
Naloxone (Narcan®) - Emergency situations: Respiratory arrest, apnea - Non-emergency situations: Respiratory depression Octreotide (Sandostatin®)
Preferred rate of infusion: Single dose over 2-3 minutes
Ondansetron (Zofran®) Paricalcitol (Zemplar®) Phenobarbital Phytonadione (Vitamin K) 1 mg/minute maximum rate— IV NOT ROUTE OF CHOICE therefore, 10mg adult dose must be over 10 minutes. RATE OF ADMINISTRATION DRUG APPROVEDIV PUSHRANGE DILUTION COMMENTS/MONITORING CAUTION: Risk of anaphylaxis Prochlorperazine (Compazine®) Pyridoxine (Vitamin B6)
Each 100mg or fraction thereof over 5 minutes. For 100mg or
Thiamine (Vitamin B1)
larger doses, equal distribution over an extended time as an infusion is preferred.
Warfarin (Coumadin) RESTRICTED IV PUSH MEDICATIONS WITH SPECIAL PRECAUTIONS
The following medications may also be pushed when necessary; however, these medications have specific guidelines for monitoring parameters and/or competency requirements. The patient will be located in an area that is able to provide appropriate monitoring. The pharmacist will ensure that the patient’s location coincides with any area restrictions as outlined in the RESTRICTED INTRAVENOUS MEDICATIONS list found on Formweb before dispensing the medication. It is the nurse’s responsibility to ensure appropriate administration and monitoring requirements are met (i.e. cardiac monitor if medication is restricted to telemetry level of care or higher). *Refer to RESTRICTED INTRAVENOUS MEDICATIONS document located on FormWeb for Location Restrictions and Approved Areas for Administration
RATE OF ADMINISTRATION APPROVEDIV PUSH DILUTION COMMENTS/MONITORING Normally loading dose administered over 1 hour followed by 1 to 1.25 gram/hour infusion. *Aminocaproic acid (Amicar) Undiluted loading dose can be given over 1 minute in ICU patients experiencing severe postoperative bleeding. Monitor neurologic status and vital signs. Watch for hypotension, bradycardia, arrhythmias.
Begin infusion at a dose of 3 mcg/kg/min at initial
signs of recovery from bolus dose. Monitor heart rate,
*Cisatracurium (Nimbex )
blood pressure, and respiratory rate. Patient must be ventilated and sedated. Cosyntropin (Cortrosyn )
Continuous observation for at least 30 minutes.
Monitor BP every 5 minutes for 30 minutes.
Small doses (1-2 mcg) may be given over 1 minute larger doses can be given over 5-10 minutes in ICU *Desmopressin Acetate patients experiencing severe postoperative bleeding. Monitor vital signs. Watch for hypotension, tachycardia and flushing.
Larger doses are normally infused over 15 to 30
minutes as IV infusion and may be administered via Piggyback to non-ICU patients.
Single dose over a minimum of 5 minutes. Monitor
Digoxin (Lanoxin )
apical pulse and BP before and after dose.
Single dose over 2 minutes. PATIENT MUST BE ON *Diltiazem (Cardizem ) A CARDIAC MONITOR DURING ADMINISTRATION. Each 2.5 mg over 1-2 minutes. Monitor for extrapyramidal symptoms. Droperidol (Inapsine®) For all doses in patients with QTc > 450 msec,
continuous ECG monitoring required for minimum of
Doses outside of OR/PACU AND greater than 1.25mg require 12-lead ECG prior to administration to
determine if prolonged QT interval exists. In addition patient must undergo continuous ECG monitoring for minimum of 2 hours ater last dose.
Single dose over 5 minutes. Monitor vital signs every Enalaprilat (Vasotec ) 15 minutes for 1 hour following each dose. May have significant drop in BP following the first dose. Fentanyl (Sublimaze ) If given for procedures, this drug requires Level II
Through saline-lock IV: Dilute to total of 5mL with
moderate sedation competency to administer. RATE OF ADMINISTRATION APPROVEDIV PUSH DILUTION COMMENTS/MONITORING
Each 0.2 mg dose over 15 seconds. Monitor BP, HR, RR. ECG and pulse oximetry recommended. If Flumazenil (Romazicon ) given for procedures, this drug requires Level II moderate sedation competency to administer. Single dose given over 1 minute. Check BP every 5 Hydralazine (Apresoline®)
minutes until stabilized at the desired level. Withdraw drug gradually to avoid rebound hypertension.
Each 20mg or fraction thereof over at least 2 minutes.
Labetalol (Normodyne®, Keep patient supine for 3 hours after infusion. Trandate ) Monitor BP before dose and every 5 minutes for 15 minutes after each dose.
Each dose should be further Singe dose over 15-20 seconds. Dose adjustment may
diluted with 10 mL NS for a be necessary for patients with renal impairment.
*Lepirudin (Refludan®)
Baseline aPTT should be obtained prior to initiating
therapy. Each 5mg must be pushed over 1-2 minutes. May
repeat 5mg boluses every 2 minutes up to 15mg.
*Metoprolol (Lopressor®) PATIENT MUST BE ON A CARDIAC MONITOR DURING ADMINISTRATION. Midazolam (Versed®)
Each dose titrated slowly over at least 2 minutes. This drug requires Level II moderate sedation competency to administer. Neostigmine (Prostigmin)
Each 0.5mg or fraction there of over 1 minute.
PHYSICIAN MUST BE
Monitor pulse rate. Pulse rate should be at least 80
beats/minute. NURSE MAY ADMINISTER WITH PHYSICIAN PRESENT AT BEDSIDE or IV NEOSTIGMINE MAY BE ADMINSTERED BY PHYSICIAN. Atropine 1mg IV and Epinephrine 1mg IV should be available at bedside. Nurse may
administer IM or SQ with out physician present
Give only through a large-bore vein (preferably via a central venous site); Use of hand or wrist veins strongly discouraged! Check patency of site before
administration. Inspect site around catheter tip and
Promethazine (Phenergan®)
extremity for swelling, blanching, bleb formation,
Administer via a running
stretched and firm skin or coolness. Ask patient to
IV
report any burning or discomfort during infusion. If extravasation suspected, stop infusion immediately and notify physician. 50 mg or fraction thereof over 10 minutes, not
exceeding 5mg/min. More rapid infusion rates may be
*Protamine
requested in ICU patients experiencing severe
postoperative bleeding. Monitor vital signs. Watch for
hypotension, bradycardia pulmonary hypertension,
dyspnea, flushing and hypersensitivity reactions.
Administered by rapid direct infusion. Monitor blood
*Vecuronium (Norcuron®)
pressure and heart rate. Patient must be ventilated and sedated.
Reproductive Health and Emergency Contraception in South Africa: Policy Context and Emerging Challenges Pranitha Maharaj and Michael Rogan1 Working Paper No 48 July 2007 PLEASE DO NOT QUOTE OR DISTRIBUTE WITHOUT PERMISSION BACKGROUND This report reflects the preliminary findings of an ongoing collaborative project to investigate the impact of trade liberalisation
< Volume 20 – June 2012> SYMPOSIUM NEWS Cochrane Canada In the News Symposium 2012 Minister Aglukkaq announces new appointment of Dr Terry Klassen to the Governing Council of the Canadian Institutes of Health Research University of Manitoba Dean of Medicine Dr Brian Postl congratulates the Faculty of Medicine’s Dr Terry Klassen on his appointment to the